NEW YORK (GenomeWeb) – Researchers at the Cleveland Clinic and colleagues have found that a testosterone-associated genetic variant can serve as a biomarker to help predict a patient's response to certain prostate cancer treatments.

Published today in two separate studies in JAMA Oncology, the researchers examined the role of the HSD3B1 (1245C) genetic variant in two prostate cancer patient populations who had received androgen deprivation therapy (ADT).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.